Hereditary/Acquired Bleeding Disorders
Efanesoctocog Alfa Granted FDA Fast Track Designation for Treatment of Hemophilia A
The US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for use of efanesoctocog alfa, a novel and investigational factor VIII therapy independent of von Willebrand Factor, in patients with hemophilia A. This agent is designed to provide near-normal factor activity levels for the majority of the week in a once-weekly prophylactic treatment regimen.
SanofiMeet the Faculty
Videos
-
Hereditary/Acquired Bleeding Disorders Insights Into Hemophilia Treatment Trends: An Interview With Michelle L. Witkop, DNP, FNP-BC, From the National Hemophilia Foundation
-
Hereditary/Acquired Bleeding Disorders Comprehensive Care of Patients With Hemophilia and von Willebrand Disease
-
Hereditary/Acquired Bleeding Disorders Evaluating Women With Bleeding Disorders: An Interview With Jacquelyn Keegan, NP, From CHLA
